Rein Therapeutics, Inc. (RNTX) Total liabilities 2016–2025
Rein Therapeutics, Inc. (RNTX) total liabilities at each fiscal year-end, per SEC filings.
$7.2MFY2025 · since FY2016: $4.1M → $7.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $7.2M | -7.2% |
| FY2024 | $7.8M | +1.1% |
| FY2023 | $7.7M | +127.9% |
| FY2022 | $3.4M | -26.1% |
| FY2021 | $4.6M | +9.5% |
| FY2020 | $4.2M | -59.9% |
| FY2019 | $10.4M | -2.7% |
| FY2018 | $10.7M | +119.0% |
| FY2017 | $4.9M | +19.8% |
| FY2016 | $4.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RNTX financial trends
RNTX RevenueRNTX Net incomeRNTX Net marginRNTX Gross profitRNTX Gross marginRNTX Operating incomeRNTX Operating marginRNTX Operating cash flowRNTX Free cash flowRNTX Capital expendituresRNTX Return on equityRNTX Stock buybacksRNTX Dividends paidRNTX Total assetsRNTX Shareholders’ equityRNTX overview →